Advertisement
Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates
From: Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
